Page 4 - Clinical Development Program News Today

PARIS, France, 28 September 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

Lebrikizumab is an investigational monoclonal antibody that binds to IL-13 protein with high affinity and inhibits its downstream signaling Positive opinion is based on Phase 3 studies which...

Daiichi Sankyo and AstraZeneca’s ENHERTU showed objective response rates of 49% and 56% with 5.4 mg/kg and 6.4 mg/kg doses, respectively, in primary analysis ENHERTU provided a median...

Designations for Daiichi Sankyo and AstraZenecas ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colorectal cancer ENHERTU has now been granted...

Daiichi Sankyo today announced that VANFLYTA® is now available by prescription in the U.S. VANFLYTA is the first and only FLT3 inhibitor to be approved by the U.S. Food and Drug Administration ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Jul 27, 2023--

Participants in SURMOUNT-3, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% from study entry...

‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) – ‒ Real-world data reinforce that first-line

‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...

First and only FLT3 inhibitor approved across three phases of AML treatment based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival Third innovative...